DeZwarteRidder schreef op 12 juli 2017 19:11:
Valeant's Valuation 'Does Not Make Sense,' Warns Piper Jaffray
[Barrons.com]
Barrons.comJuly 12, 2017
Valeant Pharmaceuticals (VRX) has more than doubled from its April lows and is up 16.5% since the start of the year. But that rally may be overoptimistic, warns Piper Jaffray's David Amsellem and Sameer Singh. They reiterated an Underweight rating and $10 price target on Valeant Wednesday. They attribute the stock's recent strength to news that recent debt transactions have delayed significant maturities until 2020 and beyond, along with recent asset sales. However, while they agree that there's less liquidity risk in the name now, they write that the company's net debt to this year's estimated EBIDTA is still well above 7 times, and trends for its crucial US segments don't look favorable. Given
Read More